Degron Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
3210 Merryfield Row, San Diego, Californ...Website
www.degrontx.comRevenue
$10.8 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Degron Therapeutics
Dago Bio aims to become the world's leading research and development company for innovative protein degradation drugs-molecular glue-based small molecule new drugs. The Dago team, composed of world-class managers and scientific leaders with international vision and rich industry experience, will focus on the discovery and verification of new, especially undruggable targets of traditional small molecule inhibitors, and the optimization of new compounds. Provide innovative solutions and paths in preclinical and clinical research. It can be used in all therapeutic areas, with the mission of benefiting human health and addressing unmet clinical medical needs.Explore more
Degron Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Degron Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Degron Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Degron Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Degron Therapeutics has new funding data
Click to see if Degron Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Degron Therapeutics
Product Launch: Get notified when Degron Therapeutics launches new products
Check if Degron Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Degron Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Degron Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Degron Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Degron Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Degron Therapeutics.
Degron Therapeutics financials insights
Gather financial insights about Degron Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$22M
2026
Other Financing Round
$40M
Degron Therapeutics Tech Stack
A closer look at the technologies used by Degron Therapeutics
Most Recent Scoops
Funding
Funding
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Sales, Food & Beverage, Hospitality, Field /Outside Sales, Field Marketing
Partnership
Partnership, Product Development, Sales, Business Development, Intellectual Property, Legal Affairs, Sales Development, Pharmaceuticals
Event
Events
Degron Therapeutics News & Media
Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders
Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation Degron will receive upfront payment and potential milestone payments of up to $1.2 billion Takeda to make equity...Degron Therapeutics Raises $22M in Series A Financing
Degron Therapeutics, a San Diego, CA and Shanghai, China-based biotechnology company, raised $22M in Series A funding. The round was led by Med-Fine Capital with participation from Dyee Capital, Baidu Venture, NeuX Capital, CO-WIN Ventures and Yuanbio Venture Capital. As part of the financing, Jing Yu, Ph.D., partner of Med-Fine Capital, joins Degron’s board of directors. […] The post Degron Therapeutics Raises $22M in Series A Financing appeared first on FinSMEs.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Degron Therapeutics
Sign Up For FreeTo access detailed company insights
Dago Bio aims to become the world's leading research and development company for innovative protein degradation drugs-molecular glue-based small molecule new drugs. The Dago team, composed of world-class managers and scientific leaders with international vision and rich industry experience, will focus on the discovery and verification of new, espec... Read More
